Oslo Cancer Cluster member Photocure announces that a new patent for Cevira® has been granted in Europe. Cevira® is one of Photocure’s promising pipeline products and is being developed as a new and innovative breakthrough for the treatment of precancerous lesions of the cervix.
The newly granted patent protects the Cevira® drug, its use and its combination with a drug delivery device, such as the Cevira® device, until 2030. This new key patent in Photocure’s Cevira® portfolio complements the company’s proprietary two European patents which protect different aspects of the Cevira® device, and which expire 2029.
Concurrently, the United States Patent and Trademark Office has issued a Notice of Allowance for Photocure’s patent application related to the Cevira® drug. A US patent protecting the Cevira® drug in a similar way as the above-mentioned European patent will issue shortly.
“The approval of this latest European patent and the Notice of Allowance for the equivalent US application is a key milestone for us in our continued work to secure the long-term value of Cevira®. The new patents further strengthen Photocure’s robust patent portfolio and provide Cevira® market exclusivity for the long-term. Cevira® is a key asset for us, with the potential to not only treat HPV induced cervical high grade disease but also to prevent the development of cervical cancer, which affects more than 500,000 women annually”, said Kjetil Hestdal, President and CEO of Photocure.
For more info: www.photocure.com